NASDAQ:MREO | Free Cash Flow | Mereo BioPharma Group plc

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2022-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$4.31M$0.00-$4.31M
2025-12-31-$7.68M$0.00-$7.68M
2025-03-31-$8.33M$20,000.00-$8.35M
2024-12-31-$9.42M$0.00-$9.42M
2024-03-31-$7.99M$0.00-$7.99M
2023-12-31-$6.79M
2023-03-31-$9.25M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$30.97M$20,000.00-$30.99M
2024-12-31-$32.83M$0.00-$32.83M
2023-12-31-$21.13M$0.00-$21.13M
2022-12-31-$48.82M$13,000.00-$48.83M